&w=3840&q=100)
Experion to invest $300 mn in VLIV, expands women-only co-living spaces
VLIV is a professionally managed co-living space offering 730 twin-sharing beds. The company, a wholly owned subsidiary of Singapore-based AT Capital Group, aims to scale to 20,000 beds over the next few years, with a long-term vision of reaching 100,000 beds nationwide.
'India's rental housing has long been fragmented and inconsistent. At Experion, we believe quality living must be built on accountability and long-term value. VLIV reflects that commitment not just by offering better residences, but a dependable, professionally managed platform. India's co-living sector is projected to grow from ₹4,000 crore in 2025 to ₹20,000 crore by 2030, with organised inventory expected to triple to nearly 1 million beds,' said B.K. Malagi, Vice Chairman, Experion.
The project features amenities including biometric access, 24/7 security, wellness zones, and certified kitchens.
'Anyone who's lived, worked, or even travelled abroad knows what well-managed rental housing can look like. And within India, lifestyles and aspirations have evolved. Yet people are still navigating outdated, fragmented options or paying too much for too little. With VLIV, we are not chasing disruption through noise; we are quietly reimagining rental living by raising the bar on quality of life and delivering it with consistency, care, and safety built on solid compliance,' said Vivek Raj, Chief Operating Officer, VLIV.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Pharma Inc gear up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
Time of India
18 minutes ago
- Time of India
Citizenship for sale? Why Canadians are joining the Caribbean passport trend
Canadians are increasingly turning to second citizenships in the Caribbean, not for passport power, but for lifestyle, financial planning, and future security . According to industry experts, demand for Caribbean " citizenship by investment " (CBI) programs is rising among Canadians who already possess one of the world's most powerful passports. Instead of using CBI to increase travel access, they're investing in these programs for peace of mind and long-term flexibility. Explore courses from Top Institutes in Please select course: Select a Course Category Technology Public Policy MBA PGDM healthcare Artificial Intelligence MCA Operations Management Finance Leadership Digital Marketing Cybersecurity Data Science Product Management Project Management Others Data Analytics Management Design Thinking Data Science CXO Degree Healthcare others Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details 'Canadians already have strong passports,' said Eric Major, CEO of UK-based Latitude Consultancy, which specializes in citizenship and residency-by-investment. 'So their motivations are usually one of three things: lifestyle, tax planning, or a Plan B, security if things become unstable at home or abroad.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Container Houses Indonesia (Prices May Surprise You) Container House | Search ads Search Now Undo The CBI programs , offered by five eastern Caribbean countries, Antigua and Barbuda, Dominica, Grenada, St. Lucia, and St. Kitts and Nevis, allow foreign nationals to obtain citizenship through either a real estate investment or a donation to a government development fund. How to qualify? Live Events To qualify, applicants undergo a rigorous due diligence process. They must hire a licensed firm, submit background checks, undergo medical exams, verify their income, and complete an identity interview. Once approved, they must fulfill the investment requirement, typically US$270,000 to US$300,000 for real estate, before receiving their citizenship certificate and passport. Canadian law permits dual and even multiple citizenships, and there is no legal limit on how many nationalities a Canadian can acquire. However, as Major points out, maintaining ties such as Canadian bank accounts or spending more than six months a year in the country can still trigger Canadian tax obligations. The programs are a significant economic driver for the Caribbean nations. In some countries, CBI revenue contributes as much as 50 percent of GDP. New regional reforms are also taking shape. As of July 1, a draft framework from the Eastern Caribbean Citizenship by Investment Regulatory Authority (ECCIRA) proposes that successful applicants must spend at least 30 days in the country within five years. If they don't, they could face fines of up to 10 percent of their investment and even risk losing their passport. With increasing global instability, demand for second citizenships, once driven by weaker passport holders, is now being led by North Americans.
Economic Times
31 minutes ago
- Economic Times
Expect pause in next policy meeting, RBI already frontloaded rate cuts: CareEdge
New Delhi: The RBI has already frontloaded the rate cuts, anticipating the moderation in inflation, and it is unlikely the central bank would go for further rate cuts unless economic growth concerns aggravate, CareEdge said in a pre-monetary policy review meeting. While the US reciprocal tariff rate (25 per cent for India) and proposed penalty are concerning, the RBI may opt to wait till "we get further clarity on this front", the rating agency said. The next bi-monthly RBI monetary policy review meeting is scheduled for August 4-6, 2025."With a forward-looking outlook, the RBI would be focusing on inflation in the quarters ahead," the report read. With CPI-based retail inflation expected to breach 4 per cent in Q4 2025-26 and average 4.5 per cent in 2026-27, the real policy rate would settle in the range of 1-1.5 per cent at the current repo rate, it asserted. "Therefore, a rate cut in the upcoming policy meeting appears unlikely. Given the incomplete transmission of the previous rate cuts, the RBI is expected to hold off on further easing, allowing time for the full impact of earlier measures to materialise," the report read."With the RBI having already frontloaded rate cuts and ensured ample liquidity, the MPC may prefer to pause for now and assess how the macroeconomic landscape evolves. Additionally, transmission of the previous rate cuts is still underway and could take some more time to show its effect on the economy."The upcoming monetary policy meeting in August takes place against the backdrop of a notable moderation in headline inflation in recent months, largely driven by easing food prices. Inflation is projected to average below the 4 per cent target over the next two quarters, supported by a favourable base and muted food global trade policy uncertainty will continue to cast a shadow on India's growth outlook; however, the overall impact is likely to be limited given India's limited merchandise trade exposure to the US economy, CareEdge a total of 100 basis point repo rate reduction since February 2025, the scope for more rate cuts was limited, RBI Governor Sanjay Malhotra had hinted after the latest monetary policy meeting. The recent frontloaded repo rate cut by the RBI was understandably aimed at boosting economy, which has relatively moderated.
